GSK To Pay Up To $4.2 Billion To Merck For Rights To Experimental Immunotherapy.

February 06, 2019

Bloomberg News (2/5, Paton, Loh) reports GlaxoSmithKline Plc will pay up to €3.7 billion ($4.2 billion) to Merck KGaA for the rights to M7824 (bintrafusp alfa), an experimental immunotherapy drug. The drug is currently being tested against Keytruda (pembr...